Recall measure seen to be hasty, less feasible

Published: 2009-04-16 07:00:00

Updated: 2009-04-16 07:00:00

The Korea Food and Drug Administration (KFDA)’s sales ban was far from being feasible since it has not confirmed whether asbestos was really detected and on top of that, the KFDA measure was based on a supplement list of eight talc suppliers, according to pharmaceutical business sources.

Last ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK